STAT+: Report: Tuberculosis R&D funding is up, but still short of goals and dominated by a few players
STAT
DECEMBER 13, 2024
billion, the highest level since tracking of funding began in 2005 and 20% more than what was seen in 2022. Just 9% came from the private sector, such as pharmaceutical companies. Specifically, the amount spent on basic research, new treatments, vaccines, and diagnostics was $1.2
Let's personalize your content